On October 29, local time, the U.S. Food and Drug Administration (FDA) approved the provision of Pfizer's new crown vaccine to children aged 5 to 11 under emergency authorization.
This time, Pfizer will provide two doses of the new crown vaccine to children aged 5 to 11, the dose is one-third of adults.
Pfizer said that studies have shown that the dose is sufficient for vaccine protection and hopes to reduce side effects.
The results of a Pfizer study on 2268 children showed that the vaccine is 91% effective in preventing symptomatic new crown infections.
According to the United States Centers for Disease Control and Prevention (CDC) statistics, among the 5-year-old to 11-year-old age group, 8,300 people have been hospitalized due to new coronary pneumonia, of which about one-third are in the intensive care unit, and the death toll is close to 100.
(Produced by Liu Yinghan)
Editor in charge: [Ji Xiang]